The 21st Century Cures Act aims to ignite innovation with perks to biopharma and medical device makers that could increase drug and device development, shrink regulation, and accelerate how quickly new treatments make it to market. Will the 21st Century Cure Act be a boon to investors in drug and medical device stocks?